Xin Zhai

846 total citations
66 papers, 695 citations indexed

About

Xin Zhai is a scholar working on Molecular Biology, Organic Chemistry and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Xin Zhai has authored 66 papers receiving a total of 695 indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Molecular Biology, 32 papers in Organic Chemistry and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xin Zhai's work include Synthesis and biological activity (22 papers), Cancer therapeutics and mechanisms (20 papers) and Lung Cancer Treatments and Mutations (17 papers). Xin Zhai is often cited by papers focused on Synthesis and biological activity (22 papers), Cancer therapeutics and mechanisms (20 papers) and Lung Cancer Treatments and Mutations (17 papers). Xin Zhai collaborates with scholars based in China and Singapore. Xin Zhai's co-authors include Ping Gong, Ming Guo, Daiying Zuo, Nan Jiang, Junjie Ma, Yanfang Zhao, Wufu Zhu, Wenfeng Gou, Lijun Xie and Tianming Zhao and has published in prestigious journals such as Science Advances, Molecules and Cancer Letters.

In The Last Decade

Xin Zhai

65 papers receiving 690 citations

Peers

Xin Zhai
Terufumi Takagi Japan
Debasis Das India
Gwan Sun Lee South Korea
Sung Yun Cho South Korea
Hui-Yi Shiao Taiwan
Eva Řezníčková Czechia
Cunlong Zhang China
Guoyi Yan China
Maeng Sup Kim South Korea
Maria Gabriella Brasca Italy
Terufumi Takagi Japan
Xin Zhai
Citations per year, relative to Xin Zhai Xin Zhai (= 1×) peers Terufumi Takagi

Countries citing papers authored by Xin Zhai

Since Specialization
Citations

This map shows the geographic impact of Xin Zhai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xin Zhai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xin Zhai more than expected).

Fields of papers citing papers by Xin Zhai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xin Zhai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xin Zhai. The network helps show where Xin Zhai may publish in the future.

Co-authorship network of co-authors of Xin Zhai

This figure shows the co-authorship network connecting the top 25 collaborators of Xin Zhai. A scholar is included among the top collaborators of Xin Zhai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xin Zhai. Xin Zhai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhao, Bing, et al.. (2025). Rational design and identification of potent imidazole-fused Autotaxin inhibitors for treatment of idiopathic pulmonary fibrosis. European Journal of Medicinal Chemistry. 298. 118011–118011.
2.
Jiang, Nan, et al.. (2025). Rational design and synthesis of 6-(piperazin-1-yl)imidazo[1,2-b]pyridazine derivatives as dual FXR/PPARδ agonists for treatment of pulmonary fibrosis. European Journal of Medicinal Chemistry. 298. 118013–118013. 1 indexed citations
3.
Zhao, Bing, et al.. (2025). Research progress on covalent inhibitors targeting alkaline amino acids. Bioorganic Chemistry. 163. 108800–108800. 1 indexed citations
4.
Ma, Deyi, et al.. (2025). Development of potent indole-3-carboxamide autotaxin inhibitors with preferred lipophilicity for in vivo treatment of pulmonary fibrosis. European Journal of Medicinal Chemistry. 288. 117398–117398. 1 indexed citations
5.
Zhao, Bing, et al.. (2024). Recent advances and challenges of revolutionizing drug-resistant tuberculosis treatment. European Journal of Medicinal Chemistry. 277. 116785–116785. 11 indexed citations
6.
Cao, Zhi, Shuyu Liu, Jiahao Zhang, et al.. (2024). Discovery of first-in-class DOT1L inhibitors against the R231Q gain-of-function mutation in the catalytic domain with therapeutic potential of lung cancer. Acta Pharmaceutica Sinica B. 14(8). 3605–3623. 3 indexed citations
7.
Han, Mei, Xiaoxuan Wang, Weiming Yang, et al.. (2023). Gain-of-function mutations in the catalytic domain of DOT1L promote lung cancer malignant phenotypes via the MAPK/ERK signaling pathway. Science Advances. 9(22). eadc9273–eadc9273. 12 indexed citations
8.
Wang, Zexin, Liwei Chen, Xiang Lin, et al.. (2022). Development of a new type of multi-functional mechanochromic luminescence material by infusing a phenyl rotator into the structure of 3,4-diphenylmaleic anhydride. New Journal of Chemistry. 46(14). 6765–6774. 2 indexed citations
9.
Wang, Xinyu, Fuyi Wang, Jiahao Zhang, et al.. (2022). Design, synthesis and anti-tumor efficacy of novel phenyl thiazole/triazole derivatives as selective TrkA inhibitors. Bioorganic & Medicinal Chemistry. 72. 116995–116995. 1 indexed citations
10.
Yang, Jing, Deyi Ma, Shuyu Liu, et al.. (2022). Design, synthesis and antitumor evaluation of ATP dual-mimic 2,4-diarylaminopyrimidine and aminoindazole conjugates as potent anaplastic lymphoma kinase inhibitors. European Journal of Medicinal Chemistry. 241. 114626–114626. 3 indexed citations
11.
Zhao, Tianming, et al.. (2021). Harmine-inspired design and synthesis of benzo[d]imidazo[2,1-b]thiazole derivatives bearing 1,3,4-oxadiazole moiety as potential tumor suppressors. Bioorganic & Medicinal Chemistry. 46. 116367–116367. 14 indexed citations
12.
Li, Zheng, et al.. (2021). Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects. Bioorganic & Medicinal Chemistry. 37. 116108–116108. 7 indexed citations
13.
Cao, Zhi, Tong Li, Xinyu Wang, et al.. (2021). Structural and PK-guided identification of indole-based non-acidic autotaxin (ATX) inhibitors exhibiting high in vivo anti-fibrosis efficacy in rodent model. European Journal of Medicinal Chemistry. 227. 113951–113951. 9 indexed citations
14.
Li, Tong, et al.. (2021). Nucleoside and Non-Nucleoside DOT1L Inhibitors: Dawn of MLLrearranged Leukemia. Mini-Reviews in Medicinal Chemistry. 21(11). 1337–1350. 5 indexed citations
15.
Li, Wei, Tianming Zhao, Yuxiang Chen, et al.. (2020). Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants. Bioorganic & Medicinal Chemistry. 28(20). 115719–115719. 10 indexed citations
16.
17.
Guo, Ming, Daiying Zuo, Jun‐Long Zhang, et al.. (2018). Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: Synthesis and biological evaluation of aminopyridine-containing diarylaminopyrimidine derivatives. European Journal of Medicinal Chemistry. 158. 322–333. 24 indexed citations
18.
19.
Zuo, Daiying, Ming Guo, Wenyu Zhang, et al.. (2017). Synthesis, biological evaluation and molecular modeling of imidazo[1,2-a]pyridine derivatives as potent antitubulin agents. Bioorganic & Medicinal Chemistry. 25(15). 4088–4099. 16 indexed citations
20.
Li, Wei, et al.. (2011). Design, Synthesis and Evaluation of Novel Rhodanine‐containing Sorafenib Analogs as Potential Antitumor Agents. Archiv der Pharmazie. 344(6). 349–357. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Terufumi Takagi Breakdown of academic impact, for papers by Debasis Das Breakdown of academic impact, for papers by Gwan Sun Lee Breakdown of academic impact, for papers by Sung Yun Cho Breakdown of academic impact, for papers by Hui-Yi Shiao Breakdown of academic impact, for papers by Eva Řezníčková Breakdown of academic impact, for papers by Cunlong Zhang Breakdown of academic impact, for papers by Guoyi Yan Breakdown of academic impact, for papers by Maeng Sup Kim Breakdown of academic impact, for papers by Maria Gabriella Brasca
Rankless by CCL
2026